VNDA earnings call for the period ending September 30, 2019.
News & Analysis: Vanda Pharmaceuticals
The stock popped after the company reported a solid quarter of operations, but serious red flags remain.
Sales of Hetlioz and Fanapt are exceeding expectations.
VNDA earnings call for the period ending June 30, 2019.
Revenue from the company's two drug products decreased 10% from the fourth quarter of 2018.
VNDA earnings call for the period ending March 31, 2019.
The S&P 500 has rarely been more expensive than it is today. That doesn't mean bargain-hunting investors are out of luck.
This high-octane midstream stock, drug developer, and retail giant have the growth potential to send their shares skyward.
Two down-on-their-luck growth stocks are worth a closer look after a poor start to 2019.
Investors looking to inject growth into their portfolios should give these companies a closer look.